|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5350836A
(en)
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0631584A4
(en)
|
1991-02-28 |
1998-07-01 |
Dana Farber Cancer Inst Inc |
DIAGNOSIS AND THERAPY OF CANCER.
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5288931A
(en)
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
JPH08504577A
(ja)
|
1992-10-30 |
1996-05-21 |
エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ |
ＴＧＦ−βの制御活性を改変するための組成物および方法
|
|
US7592428B1
(en)
|
1992-11-17 |
2009-09-22 |
Ludwig Institute For Cancer Research |
Antibodies which bind specifically to activin receptor like kinases
|
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
NZ257631A
(en)
|
1992-11-17 |
1996-03-26 |
Ludwig Inst Cancer Res |
Serine/threonine kinase domain-containing protein, dna and hosts therefor
|
|
EP0690871A4
(en)
|
1993-01-12 |
1999-10-20 |
Univ Johns Hopkins Med |
GROWTH DIFFERENTIATION FACTOR-5
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
|
JP2000514777A
(ja)
|
1995-08-14 |
2000-11-07 |
クリエイティブ バイオモレキュールズ，インコーポレイテッド |
骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合
|
|
EP0938505B1
(en)
|
1996-05-31 |
2002-03-06 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
|
|
US6190660B1
(en)
|
1996-05-31 |
2001-02-20 |
Health Research, Inc. |
Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
WO1999003992A1
(en)
|
1997-07-15 |
1999-01-28 |
Immunex Corporation |
Trail receptor
|
|
EP1071765A4
(en)
|
1998-03-13 |
2003-01-15 |
Ludwig Inst Cancer Res |
Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6413513B1
(en)
|
1998-05-22 |
2002-07-02 |
Entremed, Inc. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
US20030012792A1
(en)
|
1998-05-22 |
2003-01-16 |
Holaday John W. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
|
GB9912350D0
(en)
|
1999-05-26 |
1999-07-28 |
European Molecular Biology Lab Embl |
Modified cytokine
|
|
AU5306700A
(en)
*
|
1999-06-03 |
2000-12-28 |
Human Genome Sciences, Inc. |
Angiogenic proteins and uses thereof
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
HRP20020751B1
(hr)
|
2000-02-15 |
2011-01-31 |
Sugen |
Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
|
|
US7077836B2
(en)
|
2000-07-21 |
2006-07-18 |
Vein Rx, Inc. |
Methods and apparatus for sclerosing the wall of a varicose vein
|
|
CA2417982A1
(en)
|
2000-08-03 |
2002-02-14 |
The University Of Utah Research Foundation |
Manipulation of arterial-venous identity
|
|
DE10043481A1
(de)
|
2000-09-04 |
2002-04-11 |
Vectron Therapeutics Ag Imt |
Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
|
|
MXPA03005696A
(es)
|
2000-12-21 |
2003-10-06 |
Glaxo Group Ltd |
Pirimidinaminas como moduladores de angiogenesis.
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
FI117667B
(fi)
|
2001-07-05 |
2007-01-15 |
Univ Zuerich |
Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
|
|
CN1966725A
(zh)
|
2001-10-31 |
2007-05-23 |
爱尔康公司 |
骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
WO2003064628A2
(en)
|
2002-02-01 |
2003-08-07 |
Curagen Corporation |
Novel proteins and nucleic acids encoding same
|
|
US7045534B2
(en)
*
|
2002-02-12 |
2006-05-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of reducing angiogenesis
|
|
CA2484994C
(en)
|
2002-04-29 |
2016-06-14 |
St. Louis University |
Peptide antagonists of tgf-beta family members and therapeutic uses thereof
|
|
WO2004003163A2
(en)
|
2002-06-27 |
2004-01-08 |
University Of Utah Research Foundation |
Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
|
|
AU2003287444A1
(en)
|
2002-10-31 |
2004-05-25 |
The General Hospital Corporation |
Repairing or replacing tissues or organs
|
|
WO2005010049A2
(en)
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
WO2005044849A2
(en)
|
2003-08-05 |
2005-05-19 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
CA2554703A1
(en)
|
2004-01-27 |
2005-12-08 |
Compugen Ltd. |
Differential expression of markers in ovarian cancer
|
|
WO2005116052A2
(en)
|
2004-04-27 |
2005-12-08 |
Research Development Foundation |
ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
|
|
WO2005113590A2
(en)
*
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
|
JP2008507288A
(ja)
*
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
WO2006091930A2
(en)
|
2005-02-24 |
2006-08-31 |
Massachusetts Eye & Ear Infirmary |
Methods and compounds for promoting vessel regression
|
|
EP2322560B1
(en)
*
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
SI2447283T1
(sl)
|
2005-09-07 |
2015-12-31 |
Amgen Fremont Inc. |
Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
|
|
US20070287160A1
(en)
|
2006-04-21 |
2007-12-13 |
Chou Judy H |
Methods for high throughput screening of cell lines
|
|
WO2007143023A1
(en)
|
2006-05-31 |
2007-12-13 |
Beth Israel Deaconess Medical Center |
Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
|
|
US10059756B2
(en)
|
2006-11-02 |
2018-08-28 |
Acceleron Pharma Inc. |
Compositions comprising ALK1-ECD protein
|
|
US8642031B2
(en)
|
2006-11-02 |
2014-02-04 |
Acceleron Pharma, Inc. |
Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
|
|
KR20170012582A
(ko)
|
2006-11-02 |
2017-02-02 |
악셀레론 파마 인코포레이티드 |
Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
|
|
CL2008003302A1
(es)
|
2007-11-09 |
2009-03-06 |
Genentech Inc |
Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
|
|
CN105963695A
(zh)
|
2008-05-02 |
2016-09-28 |
阿塞勒隆制药公司 |
用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
|
|
EP2291401A2
(en)
|
2008-05-15 |
2011-03-09 |
Acceleron Pharma, Inc. |
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
|
|
WO2010060103A1
(en)
|
2008-11-24 |
2010-05-27 |
Loma Linda University |
Biomarkers for the detection of head and neck tumors
|
|
WO2010128158A1
(en)
|
2009-05-08 |
2010-11-11 |
Novartis Ag |
Diagnostic biomarkers for fibrotic disorders
|
|
WO2012106615A1
(en)
|
2011-02-03 |
2012-08-09 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
|
WO2013116781A1
(en)
|
2012-02-02 |
2013-08-08 |
Acceleron Pharma Inc. |
Alk1 antagonists and their uses in treating renal cell carcinoma
|
|
WO2014055869A1
(en)
|
2012-10-05 |
2014-04-10 |
Acceleron Pharma, Inc. |
Treatment of cancer with alk1 antagonists
|
|
AU2014388308A1
(en)
|
2014-03-28 |
2016-10-27 |
Acceleron Pharma, Inc. |
Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer
|